A biotech platform generating novel psychedelic molecules for breakthrough therapeutics
A new solution for pain management
30% of people worldwide suffer from chronic pain, and managing pain via opioids has created a crisis of its own. We’re engineering psychedelics to relieve patient suffering, avoid the prescription of more harmful substances, and reduce the burden on the healthcare system.
[Re]starting with the evidence
In 1968, psychedelic research was shut down for having ‘no therapeutic value’, and only in 2018 was psilocybin designated as a breakthrough therapy for depression. We’re working with key experts to restart clinical research of psychedelics, many of which are being studied for the first time.
Working with nature to enhance nature
Psychedelics can be made even more effective with modifications. We’re searching through 100,000+ biochemical combinations to identify and optimize the best molecules for treatment, and we’ve only scratched the surface of what is possible.
Since 1999, the yearly death count from opioid overdoses has risen 600% in the United States, with 68,630 deaths in 2020 alone.
New Solutions
Cy optimises psychedelics to generate new solutions for chronic pain.
A Timeline of Progress
Cy Biopharma AG
Oberneuhofstrasse 6
6340 Baar